JPWO2022214499A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022214499A5 JPWO2022214499A5 JP2023561752A JP2023561752A JPWO2022214499A5 JP WO2022214499 A5 JPWO2022214499 A5 JP WO2022214499A5 JP 2023561752 A JP2023561752 A JP 2023561752A JP 2023561752 A JP2023561752 A JP 2023561752A JP WO2022214499 A5 JPWO2022214499 A5 JP WO2022214499A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- amino acid
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 71
- 102000025171 antigen binding proteins Human genes 0.000 claims description 61
- 108091000831 antigen binding proteins Proteins 0.000 claims description 61
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 25
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 claims description 19
- 230000000139 costimulatory effect Effects 0.000 claims description 19
- 210000004027 cell Anatomy 0.000 claims description 17
- 102100029216 SLAM family member 5 Human genes 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 13
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 13
- 206010000830 Acute leukaemia Diseases 0.000 claims description 12
- 108091033319 polynucleotide Proteins 0.000 claims description 12
- 239000002157 polynucleotide Substances 0.000 claims description 12
- 102000040430 polynucleotide Human genes 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 108010092574 CD69 antigen Proteins 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 102000049411 human CD84 Human genes 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 44
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 7
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 6
- 102100037917 CD109 antigen Human genes 0.000 description 6
- 102100035893 CD151 antigen Human genes 0.000 description 6
- 102100025222 CD63 antigen Human genes 0.000 description 6
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 6
- 101000738399 Homo sapiens CD109 antigen Proteins 0.000 description 6
- 101000946874 Homo sapiens CD151 antigen Proteins 0.000 description 6
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 6
- 239000012472 biological sample Substances 0.000 description 6
- 229940121827 Hedgehog pathway inhibitor Drugs 0.000 description 5
- 102000023732 binding proteins Human genes 0.000 description 5
- 108091008324 binding proteins Proteins 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 3
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 description 2
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 2
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000003693 Hedgehog Proteins Human genes 0.000 description 2
- 108090000031 Hedgehog Proteins Proteins 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 230000012820 cell cycle checkpoint Effects 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- WIJZXSAJMHAVGX-DHLKQENFSA-N ivosidenib Chemical group FC1=CN=CC(N([C@H](C(=O)NC2CC(F)(F)C2)C=2C(=CC=CC=2)Cl)C(=O)[C@H]2N(C(=O)CC2)C=2N=CC=C(C=2)C#N)=C1 WIJZXSAJMHAVGX-DHLKQENFSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical group CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229950010895 midostaurin Drugs 0.000 description 2
- 108010056274 polo-like kinase 1 Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 229960001183 venetoclax Drugs 0.000 description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 2
- UJOUWHLYTQFUCU-WXXKFALUSA-N (e)-but-2-enedioic acid;6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide Chemical compound OC(=O)\C=C\C(O)=O.N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1.N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 UJOUWHLYTQFUCU-WXXKFALUSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 229940123877 Aurora kinase inhibitor Drugs 0.000 description 1
- 229940045793 B-cell lymphoma-2 inhibitor Drugs 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 229940121849 Mitotic inhibitor Drugs 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003719 aurora kinase inhibitor Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229950009240 crenolanib Drugs 0.000 description 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 description 1
- 229950010133 enasidenib Drugs 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000003117 fluorescence-linked immunosorbent assay Methods 0.000 description 1
- 229950006304 gilteritinib Drugs 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- SFNSLLSYNZWZQG-VQIMIIECSA-N glasdegib Chemical group N([C@@H]1CCN([C@H](C1)C=1NC2=CC=CC=C2N=1)C)C(=O)NC1=CC=C(C#N)C=C1 SFNSLLSYNZWZQG-VQIMIIECSA-N 0.000 description 1
- 229950003566 glasdegib Drugs 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229950010738 ivosidenib Drugs 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- ORZHZQZYWXEDDL-UHFFFAOYSA-N methanesulfonic acid;2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol Chemical compound CS(O)(=O)=O.N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 ORZHZQZYWXEDDL-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229950001626 quizartinib Drugs 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960005325 sonidegib Drugs 0.000 description 1
- VZZJRYRQSPEMTK-CALCHBBNSA-N sonidegib Chemical compound C1[C@@H](C)O[C@@H](C)CN1C(N=C1)=CC=C1NC(=O)C1=CC=CC(C=2C=CC(OC(F)(F)F)=CC=2)=C1C VZZJRYRQSPEMTK-CALCHBBNSA-N 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229950000302 vadastuximab Drugs 0.000 description 1
- BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical compound COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical group ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170976P | 2021-04-05 | 2021-04-05 | |
| US63/170,976 | 2021-04-05 | ||
| PCT/EP2022/059031 WO2022214499A2 (en) | 2021-04-05 | 2022-04-05 | Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigenscross-reference to related applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514830A JP2024514830A (ja) | 2024-04-03 |
| JPWO2022214499A5 true JPWO2022214499A5 (https=) | 2025-04-15 |
| JP2024514830A5 JP2024514830A5 (https=) | 2025-04-15 |
Family
ID=81307292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561752A Pending JP2024514830A (ja) | 2021-04-05 | 2022-04-05 | 新規腫瘍特異的抗原を使用する骨髄性障害および急性白血病の診断および処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240180963A1 (https=) |
| EP (1) | EP4320154A2 (https=) |
| JP (1) | JP2024514830A (https=) |
| KR (1) | KR20240027578A (https=) |
| CN (1) | CN117881700A (https=) |
| AU (1) | AU2022255573A1 (https=) |
| CA (1) | CA3216175A1 (https=) |
| IL (1) | IL307498A (https=) |
| MX (1) | MX2023011766A (https=) |
| WO (1) | WO2022214499A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3255414A1 (en) * | 2022-04-05 | 2023-10-12 | Alhena Science S.R.L. | TREATMENT FOR MYELOID DISORDERS AND ACUTE LEUKEMIAS TARGETING NEW TUMOR-SPECIFIC ANTIGENS |
| WO2025113635A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海祥耀生物科技有限责任公司 | 抗cd84抗体及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| ES2800328T3 (es) * | 2008-09-23 | 2020-12-29 | Yeda Res And Development Company Ltd | Métodos para diagnosticar y tratar la leucemia linfocítica crónica de linfocitos B en base a la detección e inhibición de CD84 |
| MX379256B (es) | 2013-03-15 | 2025-03-10 | Regeneron Pharma | Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos. |
| ES3063961T3 (en) * | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP2019505511A (ja) * | 2016-01-06 | 2019-02-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法 |
| WO2018002902A1 (en) | 2016-07-01 | 2018-01-04 | Glaxosmithkline Intellectual Property (No.2) Limited | Antibody-drug conjugates and therapeutic methods using the same |
| US12534532B2 (en) * | 2018-10-26 | 2026-01-27 | Crage Medical Co., Limited | CLL1-targeting antibody and application thereof |
-
2022
- 2022-04-05 US US18/285,850 patent/US20240180963A1/en active Pending
- 2022-04-05 IL IL307498A patent/IL307498A/en unknown
- 2022-04-05 JP JP2023561752A patent/JP2024514830A/ja active Pending
- 2022-04-05 EP EP22716261.7A patent/EP4320154A2/en active Pending
- 2022-04-05 KR KR1020237038027A patent/KR20240027578A/ko active Pending
- 2022-04-05 CA CA3216175A patent/CA3216175A1/en active Pending
- 2022-04-05 MX MX2023011766A patent/MX2023011766A/es unknown
- 2022-04-05 WO PCT/EP2022/059031 patent/WO2022214499A2/en not_active Ceased
- 2022-04-05 AU AU2022255573A patent/AU2022255573A1/en active Pending
- 2022-04-05 CN CN202280040186.6A patent/CN117881700A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3581651A1 (en) | Anti-gprc5d antibody and molecule containing same | |
| JP7664833B2 (ja) | 新規アゴニスト抗ｔｎｆｒ２抗体分子 | |
| CN112533950B (zh) | 抗CD3e抗体及其用途 | |
| CN119823267A (zh) | 特异性针对人类连接蛋白4的抗体 | |
| WO2018117237A1 (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| US20240409632A1 (en) | Humanized antibodies against nectin-2 and drug conjugates thereof | |
| JP2023524997A (ja) | Ｃｌｅｃ１２ａを標的とする抗体及びその使用 | |
| JP7843824B2 (ja) | 抗体および使用方法 | |
| CN114206931A (zh) | 抗pd-1抗体及其用途 | |
| JP2024001073A5 (https=) | ||
| KR20220082775A (ko) | 항-pd-1 항체 및 이의 용도 | |
| WO2023236891A1 (en) | Novel anti-lilrb4 antibodies and uses thereof | |
| JP2016524595A (ja) | Ｃｘｃｒ５に対するモノクローナル抗体 | |
| CN115916349A (zh) | 针对Lewis Y的人源化抗体 | |
| JP2022550364A (ja) | 新規抗ｐｄ－ｌ１／抗ｌａｇ－３二重特異性抗体およびその使用 | |
| EP3955925B1 (en) | Humanized anti-pd-l1 antibodies | |
| JP7264337B2 (ja) | 抗ｂ７ｓ１ポリペプチドおよびその使用 | |
| JPWO2022214499A5 (https=) | ||
| EP4725966A1 (en) | Human epidermal growth factor 3 antibody, preparation method therefor, and use thereof | |
| TWI889766B (zh) | 抗cd19抗體以及使用與製造其的方法 | |
| JPWO2023194501A5 (https=) | ||
| US12612457B2 (en) | Humanized antibodies against Nectin-2 and drug conjugates thereof | |
| CN114616243A (zh) | Car-t细胞组合物及其使用方法 | |
| WO2025061132A1 (en) | Anti-dll3 antibodies and uses thereof | |
| TW202448928A (zh) | 抗cd22抗體及其用途 |